It is imperative to weigh costs of implementing new technologies for predicting onset of Alzheimer’s disease through biomarkers and delaying onset earlier against the potential benefits of improving health. Overall… [ Get More Details ]
Donepezil, a cholinesterase inhibitor, has been found to slow progression of Alzheimer’s disease in its early stages, delaying the need for nursing home care by an average of 30 months.
[ Get More Details ]
Spinal Cord Stimulation Shows Improvements for Parkinson’s Patients
An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the Medicare costs for people with the disease in 2050 by… [ Get More Details ]